Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.18), $0.23 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $29.58 million versus the consensus estimate of $9.51 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.